Shares of Merck KGaA (OTCMKTS:MKGAF – Get Free Report) saw unusually-high trading volume on Tuesday . 686 shares were traded during trading, an increase of 10% from the previous session’s volume of 621 shares.The stock last traded at $162.55 and had previously closed at $158.25.
Merck KGaA Price Performance
The company has a debt-to-equity ratio of 0.27, a current ratio of 1.31 and a quick ratio of 0.84. The stock has a market capitalization of $20.95 billion, a price-to-earnings ratio of 24.74 and a beta of 0.96. The stock’s 50 day simple moving average is $162.24 and its 200-day simple moving average is $148.17.
Institutional Investors Weigh In On Merck KGaA
Several institutional investors and hedge funds have recently modified their holdings of the business. Frazier Financial Advisors LLC bought a new stake in Merck KGaA in the second quarter worth $25,000. Rakuten Securities Inc. bought a new position in Merck KGaA during the second quarter valued at about $27,000. Delos Wealth Advisors LLC bought a new position in Merck KGaA during the second quarter valued at about $33,000. Solstein Capital LLC acquired a new stake in shares of Merck KGaA in the second quarter worth about $33,000. Finally, Burk Holdings LLC acquired a new stake in shares of Merck KGaA in the second quarter worth about $39,000. Institutional investors and hedge funds own 0.10% of the company’s stock.
Merck KGaA Company Profile
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
See Also
- Five stocks we like better than Merck KGaA
- Home Depot Analysts See a Path to $375 and Beyond
- RTX Stock Gets a Radar Lock on a $23B Navy Win
- Berkshire Just Made a Huge Alphabet Bet—Should You Follow?
- Michael Burry Is Betting Against Palantir Again—Should Investors Care?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
